-+ 0.00%
-+ 0.00%
-+ 0.00%

Virax Biolabs posts early pilot data for ViraxImmune Long COVID test, reports 88% specificity

PUBT·05/26/2026 11:31:47
Listen to the news
Virax Biolabs posts early pilot data for ViraxImmune Long COVID test, reports 88% specificity
  • Virax Biolabs released positive early pilot data for ViraxImmune, a blood test in development for Long COVID, ME/CFS, and related post-acute syndromes.
  • Results have already been presented in a pilot dataset, with the test distinguishing patients from healthy controls.
  • An investor webcast will review the early dataset later today.
  • Work continues in an ongoing UK clinical study, with more than 120 subjects evaluated to date.
  • A larger clinical validation using samples from 300 additional participants is slated to start in Q4 2026, with results expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260730PR_NEWS_USPR_____DA63067) on May 26, 2026, and is solely responsible for the information contained therein.